Logo image of TNGX

TANGO THERAPEUTICS INC (TNGX) Stock Fundamental Analysis

NASDAQ:TNGX - Nasdaq - US87583X1090 - Common Stock - Currency: USD

2.36  -0.07 (-2.88%)

After market: 2.36 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TNGX. TNGX was compared to 572 industry peers in the Biotechnology industry. TNGX has a great financial health rating, but its profitability evaluates not so good. TNGX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TNGX had negative earnings in the past year.
In the past year TNGX has reported a negative cash flow from operations.
TNGX had negative earnings in each of the past 5 years.
In the past 5 years TNGX always reported negative operating cash flow.
TNGX Yearly Net Income VS EBIT VS OCF VS FCFTNGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

TNGX's Return On Assets of -35.01% is fine compared to the rest of the industry. TNGX outperforms 62.17% of its industry peers.
TNGX has a Return On Equity of -53.84%. This is in the better half of the industry: TNGX outperforms 63.23% of its industry peers.
Industry RankSector Rank
ROA -35.01%
ROE -53.84%
ROIC N/A
ROA(3y)-20.57%
ROA(5y)N/A
ROE(3y)-33.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TNGX Yearly ROA, ROE, ROICTNGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

TNGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNGX Yearly Profit, Operating, Gross MarginsTNGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -100 -200 -300 -400

More info and screens

7

2. Health

2.1 Basic Checks

TNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNGX has been increased compared to 1 year ago.
There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TNGX Yearly Shares OutstandingTNGX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M 80M 100M
TNGX Yearly Total Debt VS Total AssetsTNGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -0.90, we must say that TNGX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.90, TNGX perfoms like the industry average, outperforming 59.33% of the companies in the same industry.
There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.9
ROIC/WACCN/A
WACC9.44%
TNGX Yearly LT Debt VS Equity VS FCFTNGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

TNGX has a Current Ratio of 8.00. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.00, TNGX is doing good in the industry, outperforming 72.29% of the companies in the same industry.
A Quick Ratio of 8.00 indicates that TNGX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.00, TNGX is in the better half of the industry, outperforming 72.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8
Quick Ratio 8
TNGX Yearly Current Assets VS Current LiabilitesTNGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for TNGX have decreased by -6.31% in the last year.
TNGX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.66%.
EPS 1Y (TTM)-6.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.39%
Revenue 1Y (TTM)15.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.15%

3.2 Future

Based on estimates for the next years, TNGX will show a decrease in Earnings Per Share. The EPS will decrease by -6.71% on average per year.
The Revenue is expected to grow by 21.41% on average over the next years. This is a very strong growth
EPS Next Y-11.34%
EPS Next 2Y-14.68%
EPS Next 3Y-10.62%
EPS Next 5Y-6.71%
Revenue Next Year18.42%
Revenue Next 2Y-14.25%
Revenue Next 3Y-13.5%
Revenue Next 5Y21.41%

3.3 Evolution

TNGX Yearly Revenue VS EstimatesTNGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
TNGX Yearly EPS VS EstimatesTNGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TNGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNGX Price Earnings VS Forward Price EarningsTNGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNGX Per share dataTNGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

TNGX's earnings are expected to decrease with -10.63% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.68%
EPS Next 3Y-10.62%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TNGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TANGO THERAPEUTICS INC

NASDAQ:TNGX (2/21/2025, 8:00:01 PM)

After market: 2.36 0 (0%)

2.36

-0.07 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)03-17 2025-03-17/amc
Inst Owners99.16%
Inst Owner Change-95.49%
Ins Owners1.64%
Ins Owner Change-4.01%
Market Cap253.51M
Analysts86.67
Price Target11.73 (397.03%)
Short Float %5.43%
Short Ratio5.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.86%
Min EPS beat(2)27.91%
Max EPS beat(2)31.8%
EPS beat(4)2
Avg EPS beat(4)9.26%
Min EPS beat(4)-12.95%
Max EPS beat(4)31.8%
EPS beat(8)6
Avg EPS beat(8)15.52%
EPS beat(12)8
Avg EPS beat(12)12.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)104.12%
Min Revenue beat(2)45.73%
Max Revenue beat(2)162.51%
Revenue beat(4)2
Avg Revenue beat(4)41.98%
Min Revenue beat(4)-35.41%
Max Revenue beat(4)162.51%
Revenue beat(8)4
Avg Revenue beat(8)37.44%
Revenue beat(12)5
Avg Revenue beat(12)25.47%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-28.68%
EPS NQ rev (1m)-0.15%
EPS NQ rev (3m)1.6%
EPS NY rev (1m)0%
EPS NY rev (3m)2.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.84
P/FCF N/A
P/OCF N/A
P/B 1.11
P/tB 1.11
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0.4
BVpS2.13
TBVpS2.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.01%
ROE -53.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.57%
ROA(5y)N/A
ROE(3y)-33.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.32%
Cap/Sales 1.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8
Quick Ratio 8
Altman-Z -0.9
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)248.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.36%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.39%
EPS Next Y-11.34%
EPS Next 2Y-14.68%
EPS Next 3Y-10.62%
EPS Next 5Y-6.71%
Revenue 1Y (TTM)15.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.15%
Revenue Next Year18.42%
Revenue Next 2Y-14.25%
Revenue Next 3Y-13.5%
Revenue Next 5Y21.41%
EBIT growth 1Y-27.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.33%
EBIT Next 3Y-32.53%
EBIT Next 5YN/A
FCF growth 1Y-17.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.18%
OCF growth 3YN/A
OCF growth 5YN/A